科思股份 reported revenue of ¥0.89B for the period ended 2026-06-30, +23.8% year on year. Net income was ¥0.05B, a 6.0% net margin on a 27.9% gross margin. The largest revenue line is 化妆品活性成分及其原料 at 78% of the total. Free cash flow for the period was ¥0.09B.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥0.89B | +23.8% |
| Gross profit | ¥0.25B | — |
| Operating income | ¥0.06B | — |
| Net income | ¥0.05B | -15.2% |
| Gross margin | 27.9% | Net margin 6.0% |
| Revenue Q/Q | -19.7% | — |
| Segment | Revenue | Share |
|---|---|---|
| 化妆品活性成分及其原料 | ¥0.70B | 78.3% |
| 合成香料 | ¥0.18B | 20.3% |
| 其他 | ¥0.01B | 1.4% |
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥0.64B | 72.1% |
| R&D | ¥0.03B | 3.3% |
| SG&A | ¥0.11B | 12.0% |
| Tax & other | ¥0.01B | 0.7% |
| Item | Amount |
|---|---|
| Total assets | ¥4.14B |
| Total liabilities | ¥1.24B |
| Shareholders' equity | ¥2.90B |
| Equity / assets | 70.0% |
| Operating cash flow | ¥0.12B |
| Capital expenditure | ¥0.02B |
| Free cash flow | ¥0.09B |
| Cash conversion (OCF / net income) | 283% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
协创数据 ・ 科拓生物 ・ 西域旅游 ・ 锋尚文化 ・ 美畅股份 ・ 蓝盾光电 ・ 卡倍亿 ・ 南大环境 ・ 大宏立 ・ 圣元环保 ・ 杰美特 ・ 康泰医学
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies